| Valproic acid is highly teratogenic. It should not be prescribed for women if there is a possibility of becoming pregnant. | |
| Phase | Treatment | 
|---|---|
| Acute mania | Antipsychotics: aripiprazole (15-30 mg/day) Aripiprazole Alone or in Combination for Acute Mania, asenapine (10-20 mg/day), haloperidol (2-15 mg/day), cariprazine (1.5-6 mg/day), quetiapine (300-800 mg/day), olanzapine (5-20 mg/day), risperidone (1-6 mg/day) or ziprasidone (80-120 mg/day) | 
| Lithium (target concentration 0.80-1.20 mmol/l) | |
| Valproic acid* (target concentration 450-900 μmol/l) Valproate in the Treatment of Mania | |
| Carbamazepine (400-1 600 mg/day) | |
| Mood stabilizers and antipsychotics in combination | |
| Electroconvulsive therapy (in selected therapy-resistant or psychotic cases) | |
| Depression episode | Lamotrigine (50-200 mg/day) | 
| Lithium (target concentration 0.80-1.20 mmol/l) | |
| Valproic acid* (target concentration 450-600 µmol/l) | |
| Olanzapine + fluoxetine 5 + 20 - 10 + 40 mg/day | |
| Lurasidone (20-120 mg/day) | |
| Cariprazine (1.5 mg/day) | |
| Quetiapine (300-600 mg/day) | |
| Antidepressants (only in combination with mood stabilizers; discontinued gradually when remission is achieved) | |
| Electroconvulsive therapy (ECT) | |
| Mixed episode | Treatment as in mania (but specific evidence of efficacy for mixed episodes is absent for haloperidol, quetiapine and lithium) | 
| Maintenance treatment | Lithium (target concentration 0.60-0.80 mmol/l) | 
| Carbamazepine (400-1 600 mg/day) | |
| Valproic acid* (target concentration 450-900 μmol/l) | |
| Lamotrigine (50-400 mg/day; not as monotherapy in type I) | |
| Aripiprazole (15-30 mg/day), quetiapine (300-600 mg/day) or olanzapine (5-20 mg/day); depot risperidone (25-50 mg/2 weeks) | |
| The above drugs in combination | |